Frontline Immune Checkpoint Inhibitor Therapies for Non−Small Cell Lung Cancer: A New Era
A 1.0-hour Accredited On-Demand Virtual Symposium conducted in conjunction with HOPA 2021
Regeneron Pharmaceuticals, Inc and Sanofi Genzyme.
Faculty Presenters
Jordan McPherson, PharmD, MS, BCOP
Oncology Clinical Pharmacist
Huntsman Cancer Institute
University of Utah
Salt Lake City, Utah
Eve Segal, PharmD, BCOP
Lead Clinical Pharmacist, Hematology/Oncology
Seattle Cancer Care Alliance
University of Washington Medical Center
Seattle, Washington
Program Description
Non−small cell lung cancer (NSCLC) is the leading cause of cancer-associated deaths in the United States, accounting for 85% of all lung cancer diagnoses. Treatment of NSCLC is evolving with the addition of frontline therapies with immune checkpoint inhibitors (ICIs) targeting cytotoxic T-lymphocyte antigen-4 (CTLA-4), programmed cell death protein-1 (PD-1), and programmed cell death protein ligand 1 (PD-L1). This program will discuss the data supporting use of ICIs in NSCLC, including the role of biomarkers when deciding therapy, and adverse effects, with an emphasis on the management of endocrinopathies associated with these agents.
Target audience: Oncology pharmacists
Type of activity: Application
Release date: April 26, 2021
Expiration date: April 26, 2022
Time to complete activity: 1.0 hour
Fee: Free
Educational Objectives
At the completion of this activity, participants will be able to:
- Compare the clinical data for immune checkpoint inhibitor (ICI) therapies and chemotherapy in the frontline treatment of non−small cell lung cancer (NSCLC)
- Identify limitations of biomarkers when using ICIs in the treatment of NSCLC
- Characterize immune-mediated endocrinopathies and their specific management strategies
Pharmacy Times Continuing Education™ is accredited by the Accreditation Council for Pharmacy Education (ACPE) as a provider of continuing pharmacy education. This activity is approved for 1.0 contact hour (0.10 CEU) under the ACPE universal activity number 0290-0000-21-176-H01-P. The activity is available for CE credit through April 26, 2022.
Instructions for Completing the Activity and Receiving CPE Credit
To receive CPE credit, participants must complete the pretest, view the webcast in its entirety, complete the posttest, and complete the online activity evaluation. After successful completion of the online activity evaluation, you can submit your credit to CPE Monitor. You may view your credit within 48 hours at www.mycpemonitor.net. All participants must request credit before the activity expiration date. CE credit will not be issued after this date.
Disclosures
Jordan McPherson, PharmD, MS, BCOP, and Eve Segal, PharmD, BCOP, have no financial relationships with commercial interests to disclose.
Pharmacy Times Continuing Education™ Planning Staff – Jim Palatine, RPh, MBA; Maryjo Dixon, RPh; Amy Seung, PharmD, BCOP, FHOPA; Meg Croom Taylor, PharmD, CPP; Ann Marciano; Crissy Wilson; Kelly McCormick; Susan Pordon; and Brianna Winters have no financial relationships with commercial interests to disclose.
An anonymous peer reviewer is used as part of content validation and conflict resolution. The peer reviewer has no relevant financial relationships with commercial interests to disclose.
Educational Disclaimer
CPE activities are offered solely for educational purposes and do not constitute any form of professional advice or referral. Discussions concerning drugs, dosages, and procedures may reflect the clinical experience of the author(s) or they may be derived from the professional literature or other sources and may suggest uses that are investigational in nature and not approved labeling or indications. Participants are encouraged to refer to primary references or full prescribing information resources.
For questions about this internet CPE activity, please contact:
Privacy Policy and Terms of Use Information:
